Interestingly, a strong positive correlation between IGSF6 expression and tumor-infiltrating lymphocytes can be found in MMR-proficient tumors, indicating that IGSF6 could be an immunotherapy biomarker for MMR-proficient CRC patients (Fig. 1G). Here, IGSF6 is linked to neoplasm.